Telix Pharmaceuticals Ltd
ASX:TLX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.17
23.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches AUD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd
Cash from Operating Activities
Telix Pharmaceuticals Ltd
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Cash from Operating Activities
AU$23.9m
|
CAGR 3-Years
130%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immutep Ltd
ASX:IMM
|
Cash from Operating Activities
-AU$35.4m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-10%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Cash from Operating Activities
-$48.5m
|
CAGR 3-Years
22%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
CSL Ltd
ASX:CSL
|
Cash from Operating Activities
$2.8B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Cash from Operating Activities
AU$37.1m
|
CAGR 3-Years
24%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Cash from Operating Activities
-AU$38.6m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
-28%
|
|
Telix Pharmaceuticals Ltd
Glance View
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. The company is headquartered in Melbourne, Victoria and currently employs 158 full-time employees. The company went IPO on 2017-11-15. In MTR therapy, radionuclide is attached to a targeting agent such as a small molecule or antibody. This targeting agent specifically binds to tumors and delivers a radioactive payload in a selective way. The firm's lead products include TLX250/TLX250-CDx for diagnosis and treatment of renal (kidney) cancer; TLX591/TLX591-CDx for diagnosis and treatment of metastatic castrate-resistant prostate cancer and TLX101 for the treatment of glioblastoma (brain cancer).The Company's pipeline include development and commercialization of several clinical-stage products that address unmet medical needs in oncology and rare diseases.
See Also
What is Telix Pharmaceuticals Ltd's Cash from Operating Activities?
Cash from Operating Activities
23.9m
AUD
Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's Cash from Operating Activities amounts to 23.9m AUD.
What is Telix Pharmaceuticals Ltd's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 3Y
130%
The average annual Cash from Operating Activities growth rates for Telix Pharmaceuticals Ltd have been 130% over the past three years .
You don't have any saved screeners yet
